Svetinorm
Svetinorm is a complex peptide bioregulator preparation derived from liver tissue, developed at the St. Petersburg Institute of Bioregulation and Gerontology for hepatoprotective research, liver aging, and restoration of hepatic function. Part of the Cytomed line of tissue-specific bioregulators.
Svetinorm is a complex peptide preparation obtained from young animal liver tissue through acid extraction and purification. Unlike the defined-sequence tetrapeptide ovagen (TEDF), svetinorm contains a mixture of short peptides that collectively target hepatocytes and liver tissue.
Overview
Svetinorm occupies a complementary role to ovagen in Khavinson's bioregulator program. While ovagen is a single tetrapeptide (TEDF) with defined molecular properties, svetinorm is a complex preparation containing the full spectrum of regulatory peptides extractable from liver tissue. The rationale for maintaining both approaches is that complex preparations may contain peptide signals not captured by a single sequence, potentially providing broader biological coverage.
The preparation has been researched primarily in the context of liver diseases associated with aging, chronic hepatic damage, and impaired detoxification capacity. Russian clinical experience with svetinorm as a dietary supplement spans over a decade, though formal publication of controlled clinical trials in international journals remains limited.
Mechanism of Action
Svetinorm is proposed to act through the same general mechanism as other Khavinson bioregulators: tissue-specific peptides interact with DNA and chromatin structures in hepatocytes to modulate gene expression toward functional restoration. As a complex preparation, svetinorm may engage multiple regulatory targets simultaneously.
Proposed mechanisms in liver tissue include:
- Normalization of hepatocyte gene expression patterns disrupted by aging or toxic damage
- Support of detoxification enzyme systems including cytochrome P450 and phase II conjugation enzymes
- Modulation of inflammatory signaling in hepatic stellate cells and Kupffer cells
- Regulation of extracellular matrix turnover relevant to fibrosis and cirrhosis progression
The multi-peptide nature of svetinorm may provide redundant or synergistic signaling compared to single tetrapeptide approaches, though direct comparative studies between svetinorm and ovagen have not been published.
Research
Hepatoprotection in Toxic Liver Damage
Preclinical studies examined svetinorm's protective effects in animal models of toxic hepatic injury. In carbon tetrachloride-induced liver damage models, administration of liver-derived peptide preparations reduced serum transaminase levels (ALT, AST), decreased histological evidence of necrosis, and improved hepatocyte regeneration rates compared to untreated controls. These findings were consistent across multiple studies from the St. Petersburg group (Khavinson et al., 2003, Bull Exp Biol Med).
Liver Aging and Functional Decline
Age-related changes in liver function represent a significant area of research for svetinorm. Studies in aged animals demonstrated that liver-derived peptide preparations partially restored parameters that decline with aging, including albumin production, drug metabolism capacity, and bile acid synthesis. Histological improvements included reduced lipofuscin deposits and more regular hepatocyte architecture (Khavinson, 2002, Neuro Endocrinol Lett).
Cirrhosis Models
Research in experimental cirrhosis models explored whether svetinorm could modify disease progression. In rats with established liver fibrosis, treatment with hepatic peptide preparations was associated with reduced collagen deposition and decreased expression of pro-fibrotic markers including TGF-beta and alpha-smooth muscle actin in hepatic stellate cells. While these results were preliminary, they suggested potential applications in slowing cirrhotic progression.
Combined Bioregulator Approaches
Svetinorm has been studied in combination with other Cytomed bioregulators for multi-organ support in aging populations. Combinations with epithalon (pineal) and vilon (thymus) were reported to produce systemic improvements in biomarkers of aging in elderly subjects, though these studies were conducted under Russian clinical standards and have not been replicated internationally.
Safety Profile
Svetinorm has been available as a dietary supplement in Russia for over a decade with no significant adverse effects reported in available literature. As a complex of naturally derived short peptides administered orally, it is expected to have low systemic toxicity. The preparation is generally well tolerated based on reported clinical experience. No formal safety studies meeting international regulatory standards have been published. Individuals with acute liver disease, hepatic malignancies, or those receiving hepatotoxic medications should consult medical professionals before use.
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Route
- Oral (capsules)
Molecular Structure
- Formula
- Not applicable (multi-peptide preparation)
- CAS
- Not available
Research Protocols
oral
As a complex of naturally derived short peptides administered orally, it is expected to have low systemic toxicity.
Interactions
Peptide Interactions
Combinations with epithalon (pineal) and vilon (thymus) were reported to produce systemic improvements in biomarkers of aging in elderly subjects, though these studies were conducted under Russian clinical standards and have not been replicated internationally.
Unlike the defined-sequence tetrapeptide ovagen (TEDF), svetinorm contains a mixture of short peptides that collectively target hepatocytes and liver tissue.
Combinations with epithalon (pineal) and vilon (thymus) were reported to produce systemic improvements in biomarkers of aging in elderly subjects, though these studies were conducted under Russian clinical standards and have not been replicated internationally.
Quality Indicators
What to look for
- Well-established safety profile
Red flags
- Liver toxicity concerns reported
Frequently Asked Questions
References (5)
- [2]Khavinson VKh (2002). Peptides and ageing. Neuro Endocrinol Lett (2002)
- [3]Khavinson VKh et al. (2003). Effects of liver-derived peptide bioregulators on hepatic function in aging. Bull Exp Biol Med (2003)
- [5][Khavinson V et al. (2020). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung (2020)
- [1][Khavinson VKh & Malinin VV (2005). Gerontological aspects of genome peptide regulation. Karger (2005)
- [4][Ashapkin V et al. (2020). Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep (2020)
Survodutide
Survodutide (BI 456906) is a GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Administered once weekly by subcutaneous injection, survodutide has demonstrated exceptional weight loss of up to 18.7% and significant liver fat reduction in Phase 2 trials, with particular promise for obesity and MASH/NASH.
SYN-AKE (Dipeptide Diaminobutyroyl Benzylamide Diacetate)
SYN-AKE is a synthetic tripeptide that mimics waglerin-1 from the Temple Viper (Tropidolaemus wagleri), acting as a competitive antagonist at the muscular nicotinic acetylcholine receptor to reduce facial muscle contractions and expression lines.